Why Carl Icahn May Not Get His Way At Biogen Idec
This article was originally published in The Pink Sheet Daily
Executive Summary
Activist’s new plan could imply short-term gain and swift exit, may not sway shareholders in June vote, analysts say.
You may also be interested in...
Amylin Chair And Lead Independent Director Voted Off The Board
The ouster underscores the extent to which dissident shareholders, led by Carl Icahn, have had influence as Amylin hopes to win approval of a key diabetes drug.
Amylin Chair And Lead Independent Director Voted Off The Board
The ouster underscores the extent to which dissident shareholders, led by Carl Icahn, have had influence as Amylin hopes to win approval of a key diabetes drug.
Icahn And Eastbourne Win Some, Lose Some In Amylin Match
Dissident shareholders Carl Icahn and Eastbourne Capital Management have managed to snare two seats on Amylin's 12-person board of directors, enough to hold the firm's feet to the fire but not enough to command a major change of course